Compare Cassava Sciences Inc (FLNA) vs Nu Holdings Ltd (NU) Price & Performance

FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.

Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.

NU stock trades at $13.96, down 0.25% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with revenue growth from $8.3B in 2024 to $10.6B in 2025 and a net income margin of 26.72%. Recent news highlights expansion in Mexico, including banking approval and 15 million customers, signaling international growth potential. Analyst consensus is a Buy with a $14.98 price target, indicating 7% upside from current levels.

The outlook for NU remains positive due to robust earnings growth and Latin American market expansion, though risks include currency volatility and competitive pressures. With a P/E of 21.41 and ROE of 30.04%, the stock offers value if execution continues. Investors should weigh strong cash flow trends against macroeconomic headwinds in emerging markets.